1. Inicio
  2. Publicaciones
  3. Real-world Safety and Efficacy of Risankizumab in Psoriatic Patients: A Multicenter, Retrospective, and Not-interventional Study.

Real-world Safety and Efficacy of Risankizumab in Psoriatic Patients: A Multicenter, Retrospective, and Not-interventional Study.

Fecha de publicación: Fecha Ahead of Print:

Autores de IIS La Fe

Participantes ajenos a IIS La Fe

  • Martorell A
  • Santos-Alarcón S
  • Rivera-Díaz R
  • Belinchón-Romero I
  • Ruiz-Genao D
  • Romero-Maté A
  • Ruiz-Villaverde R
  • Ferrán-Farrés M
  • Gallardo-Hernández F
  • Almenara-Blasco M
  • Alonso-Suárez J
  • González-Cantero Á
  • Martínez-Lorenzo E
  • Fernández-Armenteros JM
  • de Alcázar-Viladomiu E
  • García-Latasa J
  • Rocamora-Durant V
  • Ara-Martín M
  • Mateu-Puchades A
  • Llamas-Velasco M
  • Vilarrasa-Rull E
  • Velasco-Pastor M
  • De la Cueva P
  • Carrascosa JM
  • Magdaleno-Tapial J

Grupos

Abstract

BACKGROUND AND OBJECTIVE: risankizumab-a humanized monoclonal antibody that targets the p19 subunit of IL-23-has been recently approved to treat moderate-to-severe plaque psoriasis. Real-world data based on a representative pool of patients are currently lacking. Objective To assess the mid- and long-term safety and efficacy profile of risankizumab in patients with moderate-to-severe psoriasis in the routine clinical practice. METHODS: This was a retrospective and multicenter study of consecutive psoriatic patients on risankizumab from April 2020 through November 2022. The primary endpoint was the number of patients who achieved a 100% improvement in their Psoriasis Area and Severity Index (PASI) (PASI100) on week 52. RESULTS: A total of 510 patients, 198 (38.8%) women and 312 (61.2%) men were included in the study. The mean age was 51.7 ± 14.4 years. A total of 227 (44.5%) study participants were obese (body mass index [BMI] > 30kg/m(2)). The mean baseline PASI score was 11.4 ± 7.2, and the rate of patients who achieved PASI100 on week 52, 67.0%. Throughout the study follow-up, 21%, 50.0%, 59.0%, and 66% of the patients achieved PASI100 on weeks 4, 16, 24, and 40, respectively. The number of patients who achieved a PASI = 2 was greater in the group with a BMI = 30 kg/m(2) on weeks 4 (P = .04), 16 (P = .001), and 52 (P = .002). A statistically significantly greater number of patients achieved PASI100 in the treatment-naïve group on weeks 16 and 52 (P = .001 each, respectively). On week 16 a significantly lower number of participants achieved PASI100 in the group with psoriatic arthropathy (P = .04). Among the overall study sample, 22 (4.3%) patients reported some type of adverse event and 20 (3.9%) discontinued treatment. CONCLUSIONS: Risankizumab proved to be a safe and effective therapy for patients with moderate-to-severe psoriasis in the routine clinical practice.

Copyright © 2024 AEDV. Publicado por Elsevier España, S.L.U. All rights reserved.

Datos de la publicación

ISSN/ISSNe:
0001-7310, 1578-2190

Actas Dermo-Sifiliograficas  ELSEVIER ESPANA

Tipo:
Article
Páginas:
-
PubMed:
39454868

Documentos

  • No hay documentos

Métricas

Filiaciones mostrar / ocultar

Keywords

  • Datos del mundo real; Monoclonal antibody; Psoriasis; Psoriasis Area and Severity Index (PASI); Real-world data; Risankizumab; anticuerpo monoclonal; Índice de Área y Severidad de la Psoriasis (PASI)

Cita

Compartir